Generation of 3D Whole Lung Organoids from Induced Pluripotent Stem Cells for Modeling Lung Developmental Biology and Disease
April 12th, 2021
8.8K views
The article describes step wise directed differentiation of induced pluripotent stem cells to three-dimensional whole lung organoids containing both proximal and distal epithelial lung cells along with mesenchyme.
Overview
This article presents a detailed protocol for differentiating human induced pluripotent stem cells (hiPSCs) into three-dimensional (3D) multicellular lung organoids. The method enables researchers to model human lung development and disease in vitro, overcoming the challenges associated with obtaining and culturing primary human lung tissue. The resulting organoids recapitulate key stages of lung development and contain both epithelial and mesenchymal cell populations.
Key Study Components
Area of Science
- Stem cell biology
- Developmental biology
- Organoid technology
- Respiratory research
Background
- Studying human lung development and disease is limited by the scarcity of primary lung tissue and relevant in vitro models.
- hiPSCs can be differentiated into various cell types, providing a renewable source for research.
- 3D lung organoids mimic the cellular complexity and developmental processes of the human lung.
- Organoids allow for the study of cell signaling, genetic mutations, and responses to external agents.
Purpose of Study
- To establish a reproducible protocol for generating 3D lung organoids from hiPSCs.
- To model human lung development and disease in vitro.
- To provide a platform for studying cell-cell interactions, genetic mutations, and cytotoxicity in lung tissue.
Methods Used
- Stepwise differentiation of hiPSCs into definitive endoderm, anterior foregut endoderm, and lung progenitor cells using specific growth factors and small molecules.
- Embedding differentiated cells in growth factor reduced (GFR) basement membrane matrix medium to promote 3D organoid formation.
- Sequential exposure to media supporting branching morphogenesis and maturation (including dexamethasone, cyclic AMP, and isobutylxanthine).
- Immunocytochemistry to confirm expression of lung-specific epithelial and mesenchymal markers.
Main Results
- Efficient generation of definitive endoderm and anterior foregut endoderm, confirmed by marker expression (CXCR4, SOX17, FOXA2, SOX2).
- Formation of 3D lung progenitor spheroids expressing NKX2-1.
- Development of whole lung organoids exhibiting branching morphogenesis and maturation.
- Organoids contain airway epithelial cells (KRT5, SCGB3A2, MUC5AC), alveolar epithelial cells (HOPX, SP-C), and mesenchymal cells (SMA, PDGFRα, vimentin).
Conclusions
- The protocol enables the generation of complex, multicellular lung organoids from hiPSCs.
- These organoids serve as a valuable model for studying human lung development, disease mechanisms, and therapeutic responses.
- The system allows for long-term culture, genetic manipulation, and purification of specific cell populations.
Frequently Asked Questions
What are the main advantages of using hiPSC-derived lung organoids?
They provide a renewable, manipulable source of human lung cells, enabling studies of development, disease, and therapeutic testing that are not feasible with primary tissue.
Which cell types are present in the generated lung organoids?
The organoids contain airway epithelial cells (basal, club, goblet), alveolar epithelial cells (type I and II), and mesenchymal cells (including fibroblasts and smooth muscle).
How is differentiation into lung lineages confirmed?
Differentiation is confirmed by immunocytochemistry for lineage-specific markers such as CXCR4, SOX17, FOXA2, SOX2, NKX2-1, KRT5, SCGB3A2, MUC5AC, HOPX, SP-C, SMA, and PDGFRα.
Can these organoids be used to study genetic mutations?
Yes, hiPSCs can be genetically manipulated prior to differentiation, allowing researchers to model the effects of specific mutations on lung development and function.
How long can the lung organoids be maintained in culture?
The organoids can be maintained in 3D culture conditions for many months, supporting long-term studies.
What applications are possible with this organoid system?
Applications include modeling human lung development, studying epithelial-mesenchymal signaling, testing genetic mutations, and assessing cytotoxicity of infectious agents or drugs.
Is it possible to isolate specific cell populations from the organoids?
Yes, organoids can be sorted for surface markers to purify specific cell populations for downstream analyses.
Executive Industry Relevance
Human iPSC-derived 3D lung organoids provide a renewable, physiologically relevant platform for modeling lung development and disease, addressing the scarcity of primary human lung tissue. This system enables mechanistic de-risking and target validation in respiratory research, supporting predictive confidence at early discovery and preclinical inflection points. The approach enhances portfolio decision-making by enabling functional studies of genetic mutations and cytotoxicity in a controlled, scalable environment.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables interrogation of developmental pathways and disease mechanisms in human lung tissue context.
- Supports functional target validation by modeling epithelial-mesenchymal and immune interactions.
- Facilitates mechanistic de-risking for genetic and cytotoxicity studies.
- Provides a renewable source for hypothesis-driven experimentation and portfolio triage.
Screening & Assay Development
- Establishes standardized, reproducible 3D lung models for downstream compound evaluation.
- Enables quantitative assessment of cellular responses to genetic or chemical perturbations.
- Supports assay scalability and platform reuse for high-content screening.
- Allows purification of specific cell populations for targeted analyses.
Translational & Preclinical Research
- Models disease-relevant signaling between lung epithelium, mesenchyme, and immune cells.
- Aligns with translational biomarker discovery and validation efforts.
- Enables continuity from early discovery through preclinical validation of therapeutic hypotheses.
- Supports risk-adjusted advancement decisions based on human-relevant data.
Pipeline & Workflow Integration
This protocol integrates from early discovery through lead identification and preclinical research, providing a bridge between in vitro modeling and translational studies.
- Discovery Biology: Supports hypothesis testing and pathway clarification in human lung development and disease.
- Screening: Delivers reproducible, quantitative outputs for compound and genetic perturbation studies.
- Analytics: Enables measurement of lineage-specific marker expression and functional readouts.
- Translational Research: Facilitates alignment with disease-relevant biomarkers and preclinical endpoints.
- Enterprise Reuse: Offers a scalable, renewable platform adaptable across multiple research programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in lung biology research.
- Operational Value: Standardizes workflows and enables long-term, reproducible studies.
- Strategic Value: Improves go/no-go decisions and capital efficiency by providing human-relevant data early.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of respiratory and genetic disease programs.
Implementation Considerations
- Requires expertise in stem cell culture, differentiation, and 3D organoid handling.
- Needs access to specialized cell culture infrastructure and analytical platforms for marker validation.
- Demands cross-team standardization for reproducibility and data comparability.
- Adaptation may be needed for different disease models or genetic backgrounds.
- Long-term culture and genetic manipulation require rigorous quality control and validation.
Biopharma FAQs
Why is null hypothesis testing critical in lung organoid target validation?
Null hypothesis testing enables objective evaluation of whether observed phenotypic changes in organoids are due to specific genetic or chemical interventions, supporting robust target validation and reducing false positives in early discovery.
How does independent variable isolation enhance lung progenitor differentiation studies?
Isolating variables such as growth factor timing and concentration allows precise attribution of differentiation outcomes, improving mechanistic understanding and reproducibility in the discovery pipeline.
What do quantitative marker measurements enable in 3D lung organoid assays?
Quantitative assessment of lineage-specific markers provides actionable data on differentiation efficiency and cell-type composition, informing assay optimization and downstream screening decisions.
Why are replication requirements important for cross-functional lung organoid studies?
Replication ensures that observed phenotypes and responses are consistent across experiments and teams, supporting reliable data sharing and collaborative decision-making in multi-disciplinary R&D environments.
What statistical analysis capabilities are needed before implementing lung organoid assays?
Robust statistical tools are required to analyze marker expression, differentiation efficiency, and functional outcomes, enabling confident interpretation and comparison of experimental conditions prior to broader implementation.
Chapters in this video
0:04
Introduction
1:05
Definitive Endoderm Induction from Induced Pluripotent Stem Cells (Day 1-3)
3:13
Anterior Foregut Endoderm (AFE) Induction and Lung Progenitor Cell (LPC) Differentiation
5:00
3D lung Organoid Induction (Day 16 22)
6:49
3D Lung Organoid Branching and Maturation
7:11
Results: Characterization of Endoderm and 3D Whole Lung Organoids
9:04
Conclusion
